Bay City Capital Invests in a $17 Million PIPE Offering in Interleukin Genetics, Inc.

Represented the lead investor, Bay City Capital, in a $17 million PIPE offering in Interleukin Genetics, Inc., including $12 million at initial close and $5 million optional close.

Interleukin Genetics, Inc. is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market.